Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether FIT Biotech Oy is trading at an attractive price based on the cash flow it is expected to produce in the future. But as FIT Biotech Oy has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
FIT Biotech Oy. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
FIT Biotech Oy's
is considered below, and whether this is a fair price.
Price based on past earnings
FIT Biotech Oy's earnings available for a low price, and how does
this compare to other companies in the same industry?
FIT Biotech Oy has negative assets, we can't compare the value of its assets to the Europe Biotechs industry average.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through FIT Biotech Oy's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as FIT Biotech Oy has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
FIT Biotech Oy
expected to grow at an
Unable to compare FIT Biotech Oy's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare FIT Biotech Oy's earnings growth to the Finland market average as no estimate data is available.
Unable to compare FIT Biotech Oy's revenue growth to the Finland market average as no estimate data is available.
Unable to determine if FIT Biotech Oy is high growth as no earnings estimate data is available.
Unable to determine if FIT Biotech Oy is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
FIT Biotech Oy's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
FIT Biotech Oy
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Erkki Pekkarinen has been Chief Executive Officer of FIT Biotech Oy since January 2018. Mr. Pekkarinen is the Partner and Chairman of Bio Fund Management Ltd. Mr. Pekkarinen is an Owner of BioFund. Mr. Pekkarinen has worked in BioFund since December 1999 and served as its President for ten years. He has worked lengthy periods in senior positions as institutional investor and financial advisor in private and public organizations. Along with his normal duties, he is in charge of fund formation and investor relations and is actively participating in the board work in BioFund's portfolio companies. Mr. Pekkarinen served a variety of managerial positions in investment activities and financial administration, the last one being that of Director of Finance at the Local Government Pensions Institution. He has also worked in unicipal finances and funding, conducted diversified business-related research and taught at the Helsinki School of Economics and Business Administration. In addition, he has worked extensively in consulting, for example as a Restructuring Consultant. He was a Director of FIT Biotech Oy since 2002 until January 2018. He served as Non Executive Director of Aplagon Oy. He served as a Director of Suomen pääomasijoitusyhdistys ry. He is an Advisor in corporate financial arrangements, Placement Agent and Professional Board Member. He has a M.B.A. in 1982 from the Helsinki School of Economics and Business Administration.
Insufficient data for Erkki to compare compensation growth.
Insufficient data for Erkki to establish whether their remuneration is reasonable compared to companies of similar size in Finland.
Management Team Tenure
Average tenure and age of the
FIT Biotech Oy
management team in years:
The average tenure for the FIT Biotech Oy management team is less than 2 years, this suggests a new team.
Chief Executive Officer
Chief Financial Officer
VP & Chief Scientific Officer
Chief Production Officer
Chief Quality Officer
Board of Directors Tenure
Average tenure and age of the
FIT Biotech Oy
board of directors in years:
The average tenure for the FIT Biotech Oy board of directors is less than 3 years, this suggests a new board.
Does FIT Biotech Oy (HEL:FITBIO) Fall With The Market?
Generally, an investor should consider two types of risk that impact the market value of FITBIO. … The first type is company-specific risk, which can be diversified away by investing in other companies to reduce exposure to one particular stock. … The second type is market risk, one that you cannot diversify away, since it arises from macroeconomic factors which directly affects all the stocks in the market.
In this analysis, my focus will be on developing a perspective on FIT Biotech Oy’s (HLSE:FITBIO) latest ownership structure, a less discussed, but important factor. … Insider Ownership Another important group of shareholders are company insiders. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors.
FIT Biotech Oy (HEL:FITBIO): Risks You Need To Consider Before Buying
I test FITBIO’s ratio of fixed assets to total assets in order to determine how high the risk is associated with this type of constraint. … Thus, we can expect FITBIO to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books. … However, this is the opposite to what FITBIO’s actual beta value suggests, which is higher stock volatility relative to the market.
Interested In FIT Biotech Oy (HEL:FITBIO)? Here's How It Performed Recently
After looking at FIT Biotech Oy's (HLSE:FITBIO) latest earnings announcement (31 December 2017), I found it useful to revisit the company's performance in the past couple of years and assess this against the most recent figures. … View our latest analysis for FIT Biotech Oy Did FITBIO's recent earnings growth beat the long-term trend and the industry? … HLSE:FITBIO Income Statement Apr 25th 18 We can further examine FIT Biotech Oy's loss by looking at what the industry has been experiencing over the past few years.
FIT Biotech Oy operates as a clinical-stage biotech company. The company focuses on developing antibody gene delivery technologies and gene vaccines for cancer immunotherapy, and the prevention and treatment of infectious diseases, such as HIV and tuberculosis, as well as animal vaccines. The company develops and licenses its patented gene transport unit (GTU) vector technology for new-generation medical treatments. It also markets FIT-06, a GTU-based DNA vaccine, for the treatment of HIV patients. It has a research collaboration agreement with Avacta Group plc to develop gene therapies. FIT Biotech Oy was founded in 1995 and is based in Tampere, Finland.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.